Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study

被引:8
作者
Ayvaz, Goksun [1 ]
Keskin, Lezzan [2 ]
Akin, Fulya [3 ]
Dokmetas, Hatice Sebile [4 ,5 ]
Tasan, Ertugrul [6 ]
Ar, Idilhan Baloglu [7 ]
Uren, Emel [7 ]
机构
[1] Gazi Univ, Sch Med, TR-06500 Ankara, Turkey
[2] Malatya State Hosp, Malatya, Turkey
[3] Pamukkale Univ, Sch Med, Denizli, Turkey
[4] Medipol Univ Hosp, Dept Endocrinol & Metab Dis, Istanbul, Turkey
[5] Cumhuriyet Univ, Sch Med, Sivas, Turkey
[6] Bezmialem Fdn Univ, Sch Med, Istanbul, Turkey
[7] Novartis Pharma AG, Istanbul, Turkey
关键词
DPP-4; HbA1c; Real-life; Type 2 diabetes Vildagliptin; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; BETA-CELL APOPTOSIS; COMBINATION THERAPY; MELLITUS; MANAGEMENT; HYPERGLYCEMIA; TOLERABILITY; MONOTHERAPY; GLYCEMIA; WEIGHT;
D O I
10.1185/03007995.2015.1019609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for <= 4 weeks were enrolled regardless of their previous antidiabetic therapy. Main outcome measures: Efficacy was evaluated by measuring hemoglobin A1c (HbA1c) levels. Tolerability/safety parameters evaluated included hypoglycemic events, gastrointestinal events, peripheral edema and weight gain. Results: This study enrolled 665 patients with a mean +/- standard deviation (SD) age of 55.1 +/- 10.2 years and female predominance (n = 394, 59.2%). Safety was assessed in all enrolled patients. Hypoglycemia was reported in 10 (1.5%) patients (95% confidence interval = 0.8-2.7%). Efficacy was assessed in 289 (43.5%) patients treated for 6 +/- 1 months; these patients showed a mean decrease in HbA1c of 0.8% from baseline value of 7.8% (p<0.001). The percentages of patients who achieved HbA1c targets of <= 6.5% and <= 7.0% were significantly increased, from 10.7% to 33.6% and from 22.1% to 52.6%, respectively (p<0.001 each). The decrease in HbA1c was independent of baseline HbA1c (<= 8% vs. 8-10% vs. >= 10%), age (<= 65 vs. >65 years) and body mass index (<30 vs. >= 30 kg/m(2)) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n = 29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metformin combination was associated with significant improvements in reaching target HbA1c levels, even in elderly and obese patients with T2DM. Moreover, vildagliptin and metformin demonstrated a good overall tolerability/safety profile.
引用
收藏
页码:623 / 632
页数:10
相关论文
共 40 条
[1]   The role of incretin-based therapies in prediabetes: A review [J].
Ahmadieh, Hala ;
Azar, Sami T. .
PRIMARY CARE DIABETES, 2014, 8 (04) :286-294
[2]   Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors [J].
Alanazi, Abdulrahman S. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (06) :603-613
[3]   Standards of Medical Care in Diabetes-2014 [J].
不详 .
DIABETES CARE, 2014, 37 :S14-S80
[4]  
Black N, 1996, BRIT MED J, V312, P1215
[5]   Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy - A meta-regression analysis [J].
Bloomgarden, Zachary T. ;
Dodis, Regina ;
Viscoli, Catherine M. ;
Holmboe, Eric S. ;
Inzucchi, Silvio E. .
DIABETES CARE, 2006, 29 (09) :2137-2139
[6]   Efficacy and safety of vildagliptin in clinical practice- results of the PROVIL-study [J].
Blueher, Matthias ;
Kurz, Ira ;
Dannenmaier, Simone ;
Dworak, Markus .
WORLD JOURNAL OF DIABETES, 2012, 3 (09) :161-169
[7]   Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study [J].
Bolli, G. ;
Dotta, F. ;
Rochotte, E. ;
Cohen, S. E. .
DIABETES OBESITY & METABOLISM, 2008, 10 (01) :82-90
[8]   Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J].
Bosi, Emanuele ;
Camisasca, Riccardo Paolo ;
Collober, Carole ;
Rochotte, Erika ;
Garber, Alan J. .
DIABETES CARE, 2007, 30 (04) :890-895
[9]   β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].
Butler, AE ;
Janson, J ;
Bonner-Weir, S ;
Ritzel, R ;
Rizza, RA ;
Butler, PC .
DIABETES, 2003, 52 (01) :102-110
[10]   Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study [J].
Chatterjee, Sanjay ;
Chatterjee, Sudip .
JOURNAL OF DIABETES, 2014, 6 (03) :237-242